Trazimera, illustration of injection vial form (not a photo of the actual pack)

Illustrative image.

Trazimera

Trastuzumab

Prescription required

$1800.00

420mg · 1

BrandBranded medicine· By Pfizer

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningCardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity

Cardiomyopathy: Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue TRAZIMERA for cardiomyopathy.

Infusion Reactions, Pulmonary Toxicity: Discontinue TRAZIMERA for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

Embryo-Fetal Toxicity: Exposure to trastuzumab products during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of these risks and the need for effective contraception.

Read this with the rest of the clinical information

About Trazimera

Overview

Trazimera (trastuzumab-qyyp) is a monoclonal antibody medicine that targets a protein called HER2. It is used in adults to treat breast cancer that overproduces HER2, and stomach or gastroesophageal junction adenocarcinoma that overproduces HER2 and has spread to other parts of the body. Patients are selected for treatment using an FDA-approved test for a trastuzumab product. It binds to HER2 on cancer cells, helping to limit their growth and support immune-system attack on these cells.

What it treats

- HER2-positive breast cancer in adults. - HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction in adults. Treatment eligibility is determined using an FDA-approved companion diagnostic test for a trastuzumab product.

Safety information

Side effects

Common side effects vary by treatment setting. In adjuvant breast cancer treatment, they include headache, diarrhea, nausea and chills. In metastatic breast cancer treatment, they include fever, chills, headache, infections, difficulty sleeping, cough and rash. Heart failure is also listed among the most common reactions in this setting. In metastatic gastric cancer treatment, common side effects include low white blood cell counts, diarrhea, tiredness, anemia, mouth sores, weight loss, upper respiratory tract infections, fever, low platelet counts, inflammation of moist tissue linings, inflammation of the nose and throat, and changes in taste. Serious side effects that warrant contacting a doctor include heart muscle damage or heart failure, infusion reactions, lung toxicity, and worsening of chemotherapy-related low neutrophil counts, a type of white blood cell. Trazimera can also harm an unborn baby; contact your doctor if you are pregnant or become pregnant during treatment.

FDA boxed warning

Cardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity

Cardiomyopathy: Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue TRAZIMERA for cardiomyopathy.

Infusion Reactions, Pulmonary Toxicity: Discontinue TRAZIMERA for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

Embryo-Fetal Toxicity: Exposure to trastuzumab products during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of these risks and the need for effective contraception.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Trouble breathing or a new or worsening cough. - Swelling of the face, lips, tongue or throat, which may indicate a serious allergic reaction. - Fever or chills, which may be signs of infection. Seek medical attention immediately if any of these occur.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Interactions

Tell your doctor if you are due to receive an anthracycline after stopping Trazimera. Trazimera can remain in the body for a long time, increasing the risk of heart problems with these medicines. If possible, anthracycline treatment should be avoided for up to 7 months after stopping Trazimera. If it is used, your doctor should closely monitor your heart function.

Using Trazimera

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label TRAZIMERA (TRASTUZUMAB-QYYP) KIT TRAZIMERA (TRASTUZUMAB-QYYP) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [PFIZER LABORATORIES DIV PFIZER INC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines